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Abstract Glutathione S-transferases (GSTs) are ubiquitous
multifunctional enzymes which play a key role in cellular
detoxification. The enzymes protect the cells against toxicants
by conjugating them to glutathione. Recently, a novel subgroup
of K K-class GSTs has been identified with altered substrate
specificity which is particularly important for cellular defense
against oxidative stress. Here, we report the crystal structure of
murine GSTA4-4, which is the first structure of a prototypical
member of this subgroup. The structure was solved by molecular
replacement and refined to 2.9 A î resolution. It resembles the
structure of other members of the GST superfamily, but reveals a
distinct substrate binding site.
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1. Introduction
Glutathione S-transferases (GSTs; EC 2.5.1.18) catalyze the
nucleophilic attack of the thiol group of glutathione on elec-
trophilic groups of a wide variety of hydrophobic compounds,
including environmental and industrial toxicants as well as
drugs. The glutathione adducts produced by the reaction are
often less toxic and generally have greater water solubility
than the free compounds, which facilitates their removal
from the cell. In this way, the enzymes contribute signi¢cantly
to cellular detoxi¢cation, but likewise constitute an important
factor in drug resistance of tumor cells during chemotherapy.
In addition, GSTs are involved in intracellular storage and
transport of hydrophobic non-substrate compounds including
hormones, metabolites and drugs (see for reviews [1^7]).
Based on their sequence homology, substrate speci¢city and
immunological cross-reactivity, GSTs have been grouped into
¢ve species-independent classes of isoenzymes. Four of these
classes (K, Z, W and a) comprise cytosolic enzymes, a ¢fth
rather distinct form is microsomal [1,8^10]. All cytosolic
GSTs are found to be homo- or hetero-dimeric enzymes
(from within the same class) with a relative molecular mass
of ca. 50 kDa [11]. The subunits are catalytically independent
[12].
Over the past few years, crystal structures have been re-
ported for all four classes of cytosolic GSTs [7,13^20]. The
overall structures of these proteins are similar. They comprise
an N-terminal KL domain and a C-terminal all K-helical do-
main. In the active site, which is situated in spatially equiv-
alent positions in the di¡erent classes, two distinct subsites are
present: a glutathione binding site (G-site) and a pocket
which accommodates the hydrophobic substrates (H-site). Re-
cently, also structural results on microsomal GST have been
obtained by electron di¡raction [21].
A few years ago, a subgroup of K-class GSTs has been
identi¢ed that acts primarily on endobiotic (endogenous)
rather than on xenobiotic (exogenous) substrates [22^24]. In
particular, electrophilic products of lipid peroxidation (e.g. 4-
hydroxynonenal or fatty acid or phospholipid hydroperox-
ides) can be converted by this subclass of GSTs. These com-
pounds are formed upon exposure of the cells to oxidative
stress. Many of them are highly toxic and could contribute
to the onset of severe diseases, such as atherosclerosis, which
is the leading cause of death in Western industrialized coun-
tries. The above mentioned specialized forms of GST are able
to limit the ensuing cellular damage in two ways: they reduce
fatty acid hydroperoxides through their glutathione peroxi-
dase activity, and they conjugate the already formed degrada-
tion products with glutathione. The detoxi¢cation activity of
this subgroup of GSTs has been shown to be physiologically
relevant, as demonstrated by transfection experiments [25^27].
Here, we report the crystal structure analysis of mGSTA4-4
(formerly named GST 5.7 with respect to its isoelectric point)
and present for the ¢rst time the structure of a member of this
subgroup of specialized GSTs.
2. Materials and methods
2.1. Puri¢cation and crystallization
Recombinant murine GSTA4-4 has been overexpressed in Escheri-
chia coli and puri¢ed as described earlier [24]. For crystallization, the
lyophilized protein was dissolved in water to a ¢nal concentration of
5^10 mg/ml. A broad range of conditions led to crystal formation.
Best results were obtained at 20³C using the hanging-drop vapor
di¡usion method. 3 Wl of the protein solution was mixed with equal
amounts of the reservoir solution consisting of 9^12% PEG 8000, 5^
10% MPD or 10 mM EDTA, and 0.1 M of one of the following
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few days, rod-shaped crystals appeared, which grew to a ¢nal size of
ca. 0.4U0.15U0.15 mm3 within 2 weeks. The space group was deter-
mined to be P21212, with cell dimensions of a=114.3 A î , b=95.9 A î
and c=50.8 A î .
2.2. X-ray di¡raction experiments
A 2.9 A î data set was collected at room temperature at the SRS,
Daresbury Laboratory, at beam line 9.5 (V=1.04 A î ), which was
equipped with a small MAR image plate. X-ray di¡raction data
were processed with DENZO and SCALEPACK [28], using a c cuto¡
of 0. The data set is 80.1% complete (75.8% in the last resolution shell
from 3.0 to 2.9 A î ), comprising 10477 unique re£ections with an aver-
age redundancy of 2.7. Rsym(I) is 7.6% (31.9% in the last resolution
shell) and the average I/c value 8.8.
2.3. Molecular replacement
The crystal structure of murine GSTA4-4 was solved by molecular
replacement, using the atomic coordinates of human GSTA1-1 [20]
(accessible from the PDB under ID code 1GUH) as a search model.
All calculations were carried out with the hGSTA1-1 dimer, using the
Groningen BIOMOL package. The cross-rotation function showed a
clear peak at K=133.8³, L=42.5³, Q=237.5³, and the solution of the
translation search was found to be x=0.33, y=0.24, z=0.47. The
crystallographic R-factor for this solution was 40.8%, con¢rming
also that the space group is P21212 rather than P212121.
2.4. Crystallographic re¢nement
The mGSTA4-4 crystal structure was re¢ned with the program X-
PLOR, version 3.843 [29], using the parameters of Engh and Huber
[30]. As a starting model, the hGSTA1-1 coordinates were used, of
which all non-conserved residues other than glycines were changed to
alanine residues. During the ¢rst re¢nement cycles, simulated anneal-
ing techniques were applied, later on only conventional positional
re¢nement was carried out. During the whole course of re¢nement,
except for the ¢nal cycle, strong NCS restraints were applied. The
progress during re¢nement was monitored by inspection of cA-
weighted [31] (2Fo3Fc) OMIT maps [32,33]. Manual rebuilding was
done with O [34]. In cases of doubt, the respective residues were
omitted during a subsequent re¢nement cycle, keeping the neighbor-
ing residues ¢xed.
Re¢nement converged at an R-factor of 22.9% and a free R-factor
(calculated from 10% of the re£ections) of 30.3%. The last re¢nement
cycle was repeated for all the re£ections including the test set, result-
ing in a ¢nal R-factor of 23.4%. The ¢nal model comprises residues 5^
219 of the 222 residues of molecule A and residues 5^113 and 120^217
of molecule B. Re¢nement statistics are summarized in Table 1. Co-
ordinates have been submitted to the Protein Data Bank under ac-
cession code 1GUK.
3. Results and discussion
3.1. Quality of the ¢nal model
The three-dimensional structure of mGSTA4-4 was solved
by molecular replacement using the coordinates of hGSTA1-1
[20] (Brookhaven Protein Data Bank code 1GUH) as a search
model. The ¢nal 2.9 A î model comprises residues 5^219 of
molecule A and residues 5^113 and 120^217 of molecule B.
The N- and C-terminal ends of mGSTA4-4 as well as segment
114^119 of molecule B are highly disordered in the crystal
structure. The corresponding helical segment in molecule A
is somewhat better de¢ned by electron density, as residues 115
and 119 of this molecule are involved in crystal contacts.
However, as can be seen from Fig. 1, this region is one of
the two most £exible parts of the protein structure.
Apart from the £exible regions of mGSTA4-4, the structure
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Fig. 1. Real space correlation coe¤cients for the cA-weighted (2Fo3Fc) OMIT map and mean B-values for molecule A (continuous line) and
molecule B (dotted line) of the ¢nal model of mGSTA4-4, as a function of residue number. The majority of the di¡erences occurring between
the two monomers are caused by di¡erent crystal contacts. Note that residues 114^119 of molecule B were omitted from the ¢nal model, as
these residues were found to be highly disordered in the crystal structure. The secondary structure is indicated in the top curve, shown as a 3-
value function.
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average real space correlation coe¤cient (r.s.c.c.) for the ¢nal
(2Fo3Fc) OMIT map of 0.77. The ¢nal crystallographic R-
factor is 23.4%. Root mean square deviations from ideal ge-
ometry of 0.014 A î and 1.71³ for bond lengths and angles,
respectively, and the Ramachandran plot (Fig. 2) are consis-
tent with a geometrically well de¢ned structure. The one out-
lier which is present in the Ramachandran plot (Val-174 of
molecule A) is well supported by its electron density (r.s.c.c. of
OMIT map is 0.81).
3.2. Overall structure
Murine GSTA4-4 crystallizes in space group P21212, con-
taining one dimer per asymmetric unit. This dimer most likely
corresponds to the fully functional mGSTA4-4 homodimer.
The two GST subunits are related to one another by a non-
crystallographic two-fold axis, creating a V-shaped interface
typical for GSTs in general. The two GST monomers exhibit
root mean square di¡erences (r.m.s.d.) for CK atoms of 0.11
A î , an arti¢cially low value resulting from the use of NCS
restraints during re¢nement (for comparison: the mean coor-
dinate error as determined from a Luzzati plot [35] is ca. 0.4
A î ). As the models for the di¡erent subunits are so similar and
in view of the fact that our model of molecule B contains a
gap of six missing amino acid residues (114^119), we will in
the following focus on molecule A.
Fig. 3A gives a stereo view of the overall structure of the
mGSTA4-4 monomer. It consists of two domains, an N-ter-
minal KL domain with LKLKLLK topology and a C-terminal
all K-helical domain which comprises helices K4^K9. The two
domains are separated by a pronounced cleft which harbors
the substrate (H-site) and glutathione (G-site) binding sites.
The structure is very similar to that of human GSTA1-1, the
only other K-class GST of which the structure is known to
date. R.m.s. di¡erences of CK atoms are 0.78 A î for GST
monomers. In particular, the two N-terminal domains super-
impose very well with r.m.s. di¡erences of 0.46 A î , while the C-
terminal domains (r.m.s.d.=0.85 A î compared to 1GUH) ex-
hibit somewhat greater di¡erences (shifts of 1^1.5 A î ), concen-
trated in the upper half of domain 2 as represented in Fig. 3A.
This region corresponds to the C-terminal part of helix K4,
helix K5P and connecting loop (residues 97^131) as well as to
the loop region connecting helices K6 and K7 (residues 170^
176). As residues 104^111 of helix K4 are implicated in sub-
strate binding and residues 101 and 131 have been found to be
important for binding glutathione [20], the observed di¡eren-
ces, albeit small, might not be negligible.
3.3. Glutathione binding site
As murine GSTA4-4 has a rather high Michaelis constant
(KM =0.5 mM [36], compared to a typical value of 0.1 mM for
other GSTs [37]), it was expected that glutathione could be
completely removed from the protein by extensive dialysis
against water. However, inspection of the ¢nal (2Fo3Fc)
map revealed density at positions corresponding to the bind-
ing site of glutathione in human GSTA1-1 (PDB entry
1GUH). Although glutathione is certainly not bound with
100% occupancy, it can be assumed that some glutathione is
still present in the mGSTA4-4 structure even after dialysis
against 0.1% acetic acid. Against our expectations, we are
thus not dealing with the apo-form of the protein, but with
the glutathione-bound form. However, the density of gluta-
thione is rather weak, and we therefore did not include its
coordinates in the ¢nal model of the mGSTA4-4 structure.
Considering that we are in fact dealing with the gluta-
thione-bound form of mGSTA4-4 readily explains the exist-
ence of the C-terminal helix K9. For hGSTA1-1, this helix was
found to be present in complexes with two di¡erent inhibitors
and with its glutathione conjugate, but not in the unliganded
form of the enzyme [20,38]. In analogy, we did not expect the
C-terminal residues to adopt an K-helical conformation in the
apo-form of mGSTA4-4.
A comparison of the glutathione binding site of mGSTA4-4
and hGSTA1-1 reveals two major di¡erences: one of them
concerns Arg-15 and the other one residues 41 and 45. Arg-
15 is conserved in both K-class enzymes. In the hGSTA1-1
crystal structure, this residue interacts with the sulfur atom of
glutathione [20]. It is ¢xed in this position by Glu-104, to
which it forms a salt bridge. In mGSTAA4-4, Glu-104 is
replaced by a methionine residue. Obviously, Met-104 cannot
interact with Arg-15 in the same way as Glu-104. Instead,
hydrophobic interactions are found to occur which involve
the hydrophobic part of the arginine side chain (distance
Met-104 CO to Arg-15 CQ is 3.6 A î ). Although the guanidinium
part of the Arg-15 side chain can still adopt roughly the same
conformation as in hGSTA1-1, this part of the residue is now
much less ¢xed and develops B-factors of ca. 60 A î 2. For
comparison, the Arg-15 guanidinium group of hGSTA1-1,
FEBS 19794 5-2-98
Table 1
Re¢nement statistics
Resolution range (A î ) 10^2.9
Re£ections used (Fov5) 9798
Final R-factora (%) 23.4
Average real space correlation coe¤cient
cA-weighted (2Fo3Fc) map 0.80
cA-weighted (2Fo3Fc) OMIT map 0.77
r.m.s. deviations from ideality for bond lengths (A î ) 0.014
r.m.s. deviations from ideality for bond angles (³) 1.71
Number of non-H atoms (dimer) 3432
Average B-factors (A î 2) 40.6
Secondary structure analysis according to PROCHECK [41]
Residues in most favored regions (%) 83.1
Residues in additional allowed regions (%) 14.8
Residues in generously allowed regions (%) 1.9
Residues in disallowed regions (%) 0.3
Protein Data Bank code 1GUK
aR-factor=(4NFoM3MFcN/4MFoM).
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has temperature factors of about 25 A î 2.
The other major di¡erence in the G-sites of mGSTA4-4 and
hGSTA1-1 concerns residues 41 and 45. In hGSTA1-1, these
residues are a leucine and an arginine, respectively, while they
are replaced by a tyrosine and a glutamine residue in
mGSTA4-4. Arg-45 has been found to interact with the
glutathione carboxy-terminus in hGSTA1-1 [20]. Gln-45 of
murine GSTA4-4 is much shorter and therefore cannot adopt
the same function. Tyr-41, on the other hand, has a larger
side chain than the respective Leu-41 of hGSTA1-1. In
mGSTA4-4, this residue takes over the function of Arg-45
of hGSTA1-1. The tyrosine OH atom and the arginine NH2
atom are basically superimposable. Tyr-41 is stabilized in this
position by two hydrogen bonds involving the backbone
carbonyl of residue 53 (2.9 A î ) and the amide group of
Gln-45 (3.1 A î ). However, even if Tyr-41 adopts the most
suitable conformation for binding glutathione, it cannot per-
form equally compared to Arg-45 of hGSTA1-1, as it cannot
mimic the ionic interactions with the glutathione carboxy ter-
minus.
Hence, the low binding constant of mGSTA4-4 for gluta-
thione can be explained on the basis of its crystal structure
and results from a combination of two structural di¡erences,
one involving the altered interaction of Arg-15 leading to
enhanced £exibility of its guanidinium group, and the other
one resulting from the incomplete substitution of function of
Arg-45 by Tyr-41 of mGSTA4-4.
3.4. H-site
Murine GSTA4-4 and related enzymes are remarkable for
two reasons: not only do they catalyze glutathione conjuga-
tion of endogenous substrates, in contrast to most GSTs
which act on xenobiotics, but also their substrate speci¢city
is reversed. As an example, both mGSTA4-4 and hGSTA1-1
have a similar activity for the model substrate 1-chloro-2,4-
dinitrobenzene, but they di¡er by a factor of 100 in their
activity towards 4-hydroxynonenal, a toxic electrophile de-
rived from peroxidation products of unsaturated fatty acids
[24,39,40].
The di¡erent speci¢city pattern of the two enzyme sub-
classes is expected to result from structural di¡erences in the
substrate binding site. For hGSTA1-1, this binding site has
been described for three di¡erent inhibitor complexes, involv-
ing S-benzyl-glutathione (PDB entry 1GUH [20]), ethacrynic
acid (1GSD [38]) and the glutathione conjugate of the latter
compound (1GSF [38]). Three di¡erent regions were reported
to be implicated in inhibitor binding, namely the N-terminus
of helix K1, the C-terminus of helix K4 and the region imme-
diately prior to and on one edge of helix K9.
For mGSTA4-4, the substrate binding site has been exam-
ined on the basis of a superposition of its crystal structure
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Fig. 2. Ramachandran plot as obtained from PROCHECK [41]. Val-174 of molecule A (named 1174) has unfavorable B,i angles. However, its
conformation is well supported by electron density (real space correlation coe¤cient of OMIT map is 0.81).
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of hGSTA1-1. Although in general the same protein regions
seem to be involved in substrate binding, signi¢cant di¡eren-
ces also exist.
Following the protein chain from N- to C-terminus, the ¢rst
di¡erence is found to involve Phe-10. In its conformation in
mGSTA4-4, a clash with Phe-220 of the hGSTA1-1 gluta-
thione complex would be inevitable (see Fig. 3B). Phe-220
has been found to be important for inhibitor binding in
hGSTA1-1, thus suggesting Phe-10 to be involved in inhibitor
binding of mGSTA4-4. However, in the hGSTA1-1 apo-en-
zyme, Phe-10 adopts a similar conformation as in mGSTA4-4.
The di¡erence compared to the glutathione complex of
hGSTA1-1 might therefore be due to the presence of the
apo-form in the mGSTA4-4 crystal, rather than representing
an important di¡erence compared to hGSTA1-1.
The second di¡erence involves residues 107 and 108 which
are positioned at the hydrophobic end of the substrate bind-
ing site. In mGSTA4-4, these residues are an alanine and a
valine, respectively, while in hGSTA1-1, the equivalent resi-
dues are leucines, thus residues with much longer side chains.
As a consequence of the di¡erent primary structures, the H-
site of mGSTA4-4 is signi¢cantly elongated compared to
hGSTA1-1.
Adjacent to residues 107 and 108 at the C-terminal end of
helix K4, Phe-111 is likely to play an equally important role
for interaction with hydrophobic substrates. In hGSTA1-1,
this residue is a valine. The much more bulky phenylalanine
side chain in its current position is very close in space to the
inhibitor ethacrynic acid and to Phe-222 of hGSTA1-1. Phe-
222 is disordered in the mGSTA4-4 crystal structure. Thus,
these two residues, Phe-111 of mGSTA4-4 and Phe-222 of
hGSTA1-1, are likely to have similar but highly specialized
functions regarding substrate binding of the two enzymes.
Another `almost clash' with ethacrynic acid of the
hGSTA1-1 complex 1GSF is observed for Tyr-212 of
mGSTA4-4. In hGSTA1-1, this residue is a serine. The tyro-
sine side chain is positioned near Met-208 of hGSTA1-1, a
residue replaced by a proline in mGSTA4-4. Like the func-
tional mates Phe-111/Phe-222, Tyr-212 and Met-208 also seem
to have exchanged their function for substrate binding. But
other than the former pair of residues, Tyr-212 and Met-208
not only occupy somewhat di¡erent positions, but also have
di¡erent chemical properties ^ tyrosine bearing a polar group
and being much more bulky than methionine. The positioning
of the Tyr-212 side chain is made possible by another di¡er-
ence in primary structure: the replacement of Ala-12 by gly-
cine in mGSTA4-4.
The last residue which should be mentioned here is Val-216,
which is substituted by an alanine residue in hGSTA1-1. This
residue also serves to reduce the width of the substrate bind-
ing site.
Taken together, the major di¡erences of the H-sites of
mGSTA4-4 and hGSTA1-1 concern residues 107, 108, 111,
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Fig. 3. A: Stereo view of the overall structure of one subunit of mGSTA4-4. Domain 1 and 2, the N- and C-terminus as well as helices 4, 5P
and 9 have been labelled. B: Stereo view of the substrate binding site of mGSTA4-4 (dark lines) compared to hGSTA1-1 (PDB ID code
1GUH) (light line). Both ¢gures were prepared with Molscript [42].
U. Krengel et al./FEBS Letters 422 (1998) 285^290 289208, 212, 216, and 222. While Ala-107 and Val-108 of
mGSTA4-4 serve to elongate the substrate binding site, Phe-
111, Tyr-212, and Val-216 make it narrower. This is exactly
what we would expect to happen, considering that substrates
such as 4-hydroxynonenal are longer and slimmer compared
to inhibitors like ethacrynic acid. Hence, although most of the
residues implicated in substrate binding have very similar
functions in hGSTA1-1 and mGSTA4-4 (e.g. Tyr-9 and
Arg-15), the observed di¡erences account for the high degree
of specialization of the two enzyme subclasses.
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